

Pesquisa básica e homeopatia - part 1

Basic research and homeopathy

RESEARCH IN HOMEOPATHY



```
graph TD; A[RESEARCH IN HOMEOPATHY] --> B[DOES HOMEOPATHY WORK?]; A --> C[HOW DOES IT WORK?]; B --> D[CLINICAL RESEARCH]; C --> E[COULD IT WORK BETTER?]; E --> F[BASIC RESEARCH];
```

The diagram is a flowchart on a dark blue background. At the top is a black box with yellow text 'RESEARCH IN HOMEOPATHY'. Two blue arrows point down from this box. The left arrow points to a black box with yellow text 'DOES HOMEOPATHY WORK?'. The right arrow points to a black box with yellow text 'HOW DOES IT WORK?'. From the 'DOES HOMEOPATHY WORK?' box, a blue arrow points down to a red box with yellow text 'CLINICAL RESEARCH'. From the 'HOW DOES IT WORK?' box, a blue arrow points down to a black box with yellow text 'COULD IT WORK BETTER?'. From the 'COULD IT WORK BETTER?' box, a blue arrow points down to a red box with yellow text 'BASIC RESEARCH'.

DOES
HOMEOPATHY
WORK?

CLINICAL
RESEARCH

HOW DOES
IT WORK?

COULD IT
WORK BETTER?

BASIC
RESEARCH

Pesquisa básica e homeopatia- basic research and homeopathy

- Introduction: Basic research and homeopathic principles
- Part 1: Scientific reevaluation of the “similia” principle
- Part 2: The problem of doses/potencies and related questions
- Part 3: Working hypothesis on the action mechanism of homeopathy (→ The homeopathic paradigm)

THE MAJOR TENETS OF HOMEOPATHY

*“By choosing a remedy for a given natural disease that is capable of producing a very **similar** artificial disease we shall be able to cure the most obstinate diseases”*

S. Hahnemann, Hufeland's Journal
2: 381 (1796)

**SIMILIA
PRINCIPLE**

**MICRODOSE
AND
“POTENCY”**

**TOTALITY
OF CURE**


*“A medicine whose selection has been accurately homoeopathic must be all the more salutary **the more its dose is reduced** to the degree of minuteness appropriate for a gentle remedial effect...”*

S. Hahnemann, The Organon of
Medicine (1820), par 277

*“Each individual case of disease is most surely, radically, rapidly and permanently annihilated and removed only by a medicine capable of producing (in the human system) in the most similar and complete manner **the totality** of its symptoms”*

C.F.S. Hahnemann, The Organon of Medicine (1820), par. 27

SCIENCE FIELDS INVOLVED IN THE INVESTIGATION OF HOMEOPATHIC PHENOMENA



The principle of similarity, microdose-mediated homeopathic effects and totality of cure can be investigated and understood independently of the so-called “high dilution” or “high potency” effects

- Historically, the *Similia principle* is the first “law” and the basis of the homeopathic method
- Many homeopathic drugs contain significant amount of active compounds
- In cellular models and in animals, the *Similia principle* has been widely exploited using low-doses of drugs

Pesquisa básica e homeopatia- basic research and homeopathy

Part 1: Scientific re- evaluation of the “similia” principle

Similia principle

(Principle of Similarity)


when a substance
is able to *induce* a series of symptoms
in a healthy living system
it would be also able under certain circumstances
to *cure* these symptoms
when applied at low doses
(“*similia similibus curentur*”)

*“Through the **similar** the disease develops and through the employment of the **similar** the disease is healed.*

So that which produces urinary tenesmus in the healthy, cures it in disease.

Cough is provoked and healed through the same agent, just as in the case of urinary tenesmus”

Littre's Oeuvres Completes d'Hippocrates,
Paris, 1839, 6, 334.



Hippocrates
(460-377 B.C.)

A scientific reevaluation of Similia principle

=

“inversion of effects”

- *Biphasic or polyphasic dose-response effects*
- *Reversal of inhibition during time*
- *Inverse effects in systems at different physiological states*

Bellavite et al., *Br.Hom.J.* 86:73-85, 1997

Bellavite et al., *Medical Hypoth.*, 49: 203-212, 1997

Bellavite et al. *Ann. Ist. Sup. Sanità* 35(4): 517-527, 1999

EXAMPLES OF INVERSE EFFECTS WITH HOMEOPATHIC DILUTIONS


System	Agent	Conventional effect	Inverse/homeopathic effect	Ref.
Basophils	Histamine Apis mellifica	Pro-inflammatory agents	Histamine (up to 60x) and Apis mellifica (10c)	Poitevin 1988 S.Laudy 1991 Belon 1996-99
Rat Guinea pig	Histamine Lung Histamine Apis mellifica	Pro-inflammatory agent	Histamine (30x), Lung histamine (18c) and Apis mellifica (7c/10c) reduce inflammation symptoms	Bastide 1975 Poitevin 1988 Bildet 1990 Conforti 1993
Rat Mouse	Arsenic trioxide Arsenicum album	Whole body and liver toxicity	Arsenic trioxide (7c and 17c) and Arsenicum album (30c) protect from intoxication and increase Urinary elimination	Lapp 1955 Wurmser 1955 Cazin 1987 Cazin 1991 Khuda-Bukhsh 1998-2000
Rat liver	Phosphorus	Hepatotoxicity	Phosphorus (30x) protects from toxic hepatitis	Bildet 1984 Guillemain 1987 Palmerini 1993 Gomez 1999
Tadpoles	Thyroxine	Increases the rate of metamorphosis	High dilutions (30x) inhibit the metamorphosis	Endler 1991-98

MODELLING THE SIMILIA PRINCIPLE

- Cells
 - Hormesis (stimulation of growth by low doses of toxic compounds or radiations)
 - Heat shock proteins
 - Gating theory (cyclic AMP)
- Whole organism
 - Immune network and tolerance (animal & humans)
 - Chaos and attractors
 - Neuroendocrine feedback regulation
- Unifying model
 - Regulation of stressed homeostatic networks
(→ the homeopathic paradigm)

The “Arndt-Schulz law”


“Weak stimuli slightly accelerate vital activity, medium strong stimuli raise it, strong ones suppress it and very strong ones arrest it”




H.Schulz,
Arch fuer Physiol 1888; 42: 517-541

“Hormetic” effects (stimulation by low doses of toxic compounds)

A. DOSE/EFFECT PLOT



B. TIME-COURSE PLOT



EXAMPLES OF INVERSE EFFECTS IN LABORATORY SYSTEMS



System	Agent	First effect	Inverse effect	Ref.
Yeast	Heavy Metals	Block growth	Low doses increase growth	Schulz 1988 Martius 1923 Stebbing 1982
Fibroblasts Wheat	Arsenite Cadmium	Cell toxicity	Low doses protect from toxicity or stimulate DNA synthesis	vanWijk 1995 vanWijk 1997 V.Zglinicki 1992 Betti 1997-2000
Neurons	Naloxone	Antagonizes morphine	Low doses enhance the effect of morphine	Crain 1995
Neurons	β -amyloid	Toxic for mature cells	Promotes growth of young cells	Yankner 1990
Epithelial cells Tumor cells	Oxidants	Short-term/high doses decrease viability	Long-term/low doses increase viability	Da Silva 1996 Jenkins 1995
Macrophages	Interfererons Endotoxins	Activation of resting cells	Inhibition of pre-activated cells	Adams 1992
Platelets	Diclofenac	Inhibit functions	Stimulate platelet adhesion	Andrioli-Bellavite 1997
Leukocytes	Bacterial peptides	Stimulate adherence	Low doses inhibit adherence	Bellavite 1993-1997

INVERSE EFFECTS OF BIOLOGICAL COMPOUNDS ON MACROPHAGES

(From: Inflammation, Raven Press, 1992. Gallin et al. ed.)

INTERFERON- α , β
INTERFERON- γ
TNF- α
IL-6
MCP-1
GM-CSF
LPS
MODIFIED LDL

ACTIVATION




SUPPRESSION

INTERFERON- α , β
TNF- α
IL-4
TGF- β
LPS
PGE₂
DEXAMETASONE
SEROTONIN

BASOPHIL ACTIVATION

 **Anti-IgE or allergenic compounds
(conventional doses)**




IgE

CD63

Resting cell



Stimulation




Activated cell
“Degranulation”

THE FAMOUS EXPERIMENT OF BENVENISTE (DAVENAS ET AL., NATURE 1988)

* Ultra-high dilution (up to 10^{-120} Moles/L)
of **Anti-IgE**



→
Stimulation




Resting cell

Activated cell



EXPERIMENTS OF POITEVIN ET AL. (BR. J. CLIN. PHARM. 1988)

Homeopathic drugs
LUNG HISTAMINE (5CH, 15 CH)
APIS MELLIFICA (9CH)

Anti-IgE
(Medium doses)



Resting cell




Lack of response
to Anti-IgE



EXPERIMENTS OF SAINTE LAUDY, BELON ET AL. (1989-1999)

Ultra-high dilution of **Histamine**

Anti-IgE
(Medium doses)



Resting cell



Lack of response
to Anti-IgE

Investigations on complex responses of neutrophils to bacterial products


- **Inverse effects of different doses**
- **Homologous priming and desensitization**

Hormesis

is a special application of the similia principle at the biological and physiopathological level, but it does not represent “the” explanation of homeopathic effects, which may have further and more complex implications at the level of whole human organism.


Dual effects of podophyllum on human neutrophils

(Data from Chrumbolo and Bellavite, *Brit. Hom. J.* 86: 16-26, 1997)



Priming and desensitization of human neutrophils

(Data from Bellavite et al., *Cell Biochem. Funct.* 11: 93, 1993)



Priming


*is a state of hyperactivation in response to a given stimulant, which characterizes a cell or a system after it has received pretreatment with low doses of the same stimulant
(homologous priming)
or of other stimulants of a different type
(heterologous priming)*

Desensitization

is a state characterized by lack of responsiveness to a given stimulus after the cell or the organism have received pretreatment with the same stimulant (homologous desensitization) or with different stimulants (heterologous desensitization)


A typical example of inverse effects of different doses of a stimulant (FMLP) on the adhesion of human neutrophils

(Data from Bellavite et al., *Cell Biochem. Funct.* 11: 231, 1993)




Inverse effects of different doses of fMLP on the adhesion of inflammatory human neutrophils

(Data from Bellavite et al., *Inflammation*. 18: 575, 1994)




In vivo skin
inflammation



Adhesion

+ Bacterial
fMLP

HIGH DOSE
(10^{-6} M)




Increased adhesion















+ Bacterial
fMLP

LOW DOSE
(5×10^{-9} M)












Decreased adhesion

Summary of the dose-dependence of responses of human neutrophils to bacterial peptides (fMLP)

TESTED FUNCTION	LOW DOSES (10^{-8} TO 10^{-10} M) (8x to 10x)	HIGH DOSES (10^{-5} TO 10^{-7} M) (5x to 7x)
SUPEROXIDE PRODUCTION	 (NO EFFECT)	
ADHESION (NORMAL CELLS)	 (NO EFFECT)	
ADHESION (LPS-PRIMED CELLS)		
fMLP RECEPTORS	(PRIMING) 	 (DESENSITIZATION)
[Ca ⁺⁺] _i INCREASE		
[cAMP] _i INCREASE		

Specificity of the inhibition of adhesion by FMLP in human neutrophils pre-treated with various agents

PRE-TREATMENT	STIMULANT (low doses)	EFFECTS of STIMULANT	
		<u>ADHESION</u>	<u>cAMP</u>
LPS	FMLP		
LPS	Concanavalin A		NO EFFECT
LPS	Phorbol esters		NO EFFECT
TNF- α	FMLP		
Inflammation	FMLP		
Inflammation	Concanavalin A		NO EFFECT

The complexity of *in vitro* regulation of human neutrophils (summary)

- Neutrophils exposed to LOW doses of fMLP are primed to further stimuli, while neutrophils exposed to HIGH doses are desensitized
- Adhesion of NORMAL neutrophils is activated by high doses of fMLP, while adhesion of LPS-TREATED neutrophils is inhibited by low doses of fMLP
- Inverse effects can be observed in several (but not all) models, thus the experimental conditions (doses, type of stimulant, cell treatment, cell function) must be carefully set

POSSIBLE MODELS EXPLAINING INVERSE EFFECTS (= SIMILIA PRINCIPLE) AT A CELLULAR LEVEL


- Detoxification enzymes (gene induction and activation)
- Heat shock proteins (stress proteins, chaperonins)
- Various receptors (different affinity and different coupling with effectors)
- Gating theory (signal transduction)

SUBOPTIMAL CELLULAR STRESS RESPONSE

EXCESS OF
TOXIC LOAD

HORMONAL
AND/OR
METABOLIC
IMBALANCE
OF GENE
EXPRESSION

SUBOPTIMAL
PROTEIN
SYNTHESIS



HEAT-SHOCK PROTEINS AND HOMEOPATHY

R. Van Wijk and F.A.C. Wiegant (1995-1998)

“Such a condition of the cell, in which the reaction to the threat is not optimal, may be considered pathological. The cell could then be considered a “sick system” with the damage insufficiently compensated”

“Here the question is whether compensation can be increased and whether the development of resistance can be stimulated, and if so, how”

HEAT-SHOCK PROTEINS AND HOMEOPATHY

R. Van Wijk and F.A.C. Wiegant (1995-1998)

“Self-recovery will be stimulated with a smaller dose of the substance responsible for disturbing the system in the first place”

“Self-recovery is defined on the cellular level as supplementing the arsenal of protective proteins, stimulating resistance for the disturbing agent and temporarily stimulating proliferation in compensation for cell death”


HYPOTHETICAL MODEL OF THE REGULATION OF CELLULAR STRESS RESPONSE BY LOW DOSES OF TOXIC COMPOUNDS

**HIGH DOSES
OF TOXIC
COMPOUND**

**INCREASE OF
FREE AND
AVAILABLE
HSP**

**LOW-DOSE
“SIMILE”
COMPOUND**

**INCREASE OF
HSP mRNA
TRANSCRIPTION**



THERAPEUTIC APPLICATIONS OF HEAT SHOCK PROTEINS

S.M. Edginton Bio/TECHNOLOGY VOL. 13, DECEMBER 1995, p. 1442-
1444

- Immune modulation
- Cancer therapy
- Vaccines and Adjuvants
- Heart attack and stroke

EXAMPLES OF INVERSE EFFECTS IN ANIMAL SYSTEMS

System	Agent	First effect	Inverse effect	Ref.
Rat blood	Acetylsalicylic acid	Inhibit platelet aggregation	Very-low doses have thrombogenic activity	Doutremepuich 1994
Dog heart	Ischemia	Causes infarction	Ischemic preconditioning protects from infarction	Cohen 1996
Mouse prostate	Estrogens	Inhibit growth	Low doses promote growth	VomSaal 1997 Gupta 2000
Mouse and rat immune system	Protein antigens	Induce autoimmune disease	Oral administration protects and cure autoimmunity	Miller 1992 Weiner 1997 Wu 1998
Rat arthritis	Naloxone	Hyperalgesia	Low doses have antinociceptive effects	Kayser 1988
Rat liver	Carbon tetrachloride	Toxicity	Low doses protect from liver toxicity	Ugazio 1972 Mehendale 1991 Pound 1993
Rat immune system	Killed mycobacteria	Induce arthritis	Intraperitoneal low-doses cure arthritis	Conforti-Bellavite 1995-2000

TREATMENT OF ORGAN-SPECIFIC AUTOIMMUNE DISEASES IN ANIMALS USING THE “SIMILE” SUBSTANCE

DISEASE	ADMINISTERED COMPOUND
Experimental allergic encephalomyelitis (Lewis rat, guinea pig)	Myelin basic protein Oral: 3-10 mg (no effect with 50 mg) Aerosol: 0.005-5 mg
Collagen-induced arthritis Adjuvant-induced arthritis BSA-induced arthritis (Lewis rat)	Collagen type II and type I Oral: 0.003 mg (no effect with 0.3 mg)
Spontaneous autoimmune diabetes (Mouse)	Insulin Oral: 1 mg (no effect with 5 mg)
Experimental autoimmune myasthenia gravis (Lewis rat)	Acethylcholine receptor Oral: 20 mg

Adapted from Weiner et al., Annu. Rev. Immunol. 1994; 12: 809-837. The daily intake indicated

ANIMAL MODELS OF INVERSION OF EFFECTS (Verona group)

■ Effects of high dilutions of histamin and other natural compounds on acute inflammation in rats

Conforti, A., Signorini, A. and Bellavite, P. (1993) In: Omeomed92 (C. Bornoroni ed.). Editrice Compositori, Bologna. pp 163-169.

■ Intraperitoneal administration of adjuvant inhibits the development of adjuvant arthritis in rats

Conforti, A., Lussignoli, S., Bertani, S., Ortolani, R., Verlato, G. and Bellavite, P. (1995). *Int. J. Immunopathol. Pharmacol.* 8 (2): 113-121.

■ Specific and long-lasting suppression of rat adjuvant arthritis by intraperitoneal low-dose of *Mycobacterium butiricum*.

Conforti A., Lussignoli, S., Bertani, S., Verlato, G., Ortolani, R., Bellavite, P. and Andrichetto, G. (1997) *Eur. J. Pharmacol.* 324: 241-247.

■ Suppression of adjuvant arthritis in rats by intraperitoneal *Mycobacterium butyricum*

Conforti, A., Lussignoli, S., Bertani, S., Ortolani, R., Brendolan, A., Cestari, T., Andrichetto, G. and Bellavite, P. (1998). *J. Chemother.* 10: 169-172

■ Dual effects of a homeopathic mineral complex on carrageenan-induced oedema in rats

Bertani, S., Lussignoli, S., Andrioli, G., Bellavite, P. and Conforti, A. (1999) *Br. Hom. J.* 88: 101-105

EXAMPLES OF INVERSE EFFECTS IN HUMANS

Condition	Agent	First effect	Inverse effect	Ref.
Respiratory allergy	Allergens	Cause allergy	Very low doses reduce allergy symptoms (also high dilutions 30c)	Black 1927 Scadding 1986 Malling 1998 Reilly 1987-2000
Bleeding	Acetylsalycilic acid	Increase bleeding time	Very low doses (5c=0.000000001 mg) decrease bleeding time	Doutremepuich 1987-1998
Respiratory disease	Nitric oxide	Toxic inhalant for airways (pollutant)	Inhaled low doses cure airways obstruction	Quinn 1993 Kinsella 1999
Cardiovascular disease	Alcohol Digitalis	High doses are toxic	Low doses protect and cure	Friedman 1986 Davis 1990 Goodman 1990
Rheumatoid arthritis	Collagen	Autoantigen	Oral very low doses cure the disease (in some subjects)	Trentham 1993 Weiner 1997
Cancer	Ionizing radiations	Cancerogenic	Epidemiological evidence of protection by low doses	Goldman 1996
Nervous system	Tryciclic antidepressants	Mood elevation in depressed patients	Sleepiness, low blood pressure, dysphoria	Goodman 1990

Reviews: Bellavite/Signorini 1995; Eskinazi 1999

EXAMPLES OF MODERN SCIENTIFIC THERAPIES IN AGREEMENT WITH THE PRINCIPLE OF SIMILARITY

- Cytokine therapy in the immunocompromised host
- Endotoxins as immunostimulants
- Treatment of immune disorders with immunoglobulins
- Nitric oxide in respiratory diseases
- Oral myelin in multiple sclerosis
- Oral collagen in rheumatoid arthritis
- Bacterial extracts in recurrent bronchitis
- Nasal allergens in allergic diseases
- Cancer vaccines made with tumour antigens or cells

SUMMARY OF EXPERIMENTAL EVIDENCE OF “SIMILIA PRINCIPLE”/INVERSION OF EFFECTS

- Stimulation or protection by low doses of toxic compounds (typical hormesis effect) on cell and animal models
- Inhibition of specific cellular activities by low doses of stimulating compounds
- Inhibition or protection of autoimmunity by low doses of antigen
- Paradoxical effects of drugs
- Therapeutic effects of low doses/high dilutions of toxic compounds in humans (classical homeopathy)